Tumour-associated splice variants of fibronectin are a major source of tumour-matrix associated t... more Tumour-associated splice variants of fibronectin are a major source of tumour-matrix associated targets and are proving very successful in the development of clinical agents to treat cancer. One of the first monoclonal antibodies to be produced to this target, murine BC-1, recognises a cryptic epitope in domain 7 of the B-form splice variant (EDB-FN). Antibody fragments based on this immunoglobulin (IgG) were unstable, but BC-1 humanisation provided an opportunity to produce a more stable single-chain Fv (scFv). The variable domains of the humanized BC-1 IgG were sub-cloned and constructed into a scFv (HuBC-1 scFv) which was successfully expressed in Escherichia coli. The scFv retained its conformationally- sensitive epitope recognition and demonstrated a good affinity to the target of around 50 nM as measured by ELISA, Surface Plasmon Resonance and Flow Cytometry. Furthermore, the scFv was thermostable and stable in serum allowing substantial localisation to human tumours grown in mouse xenograft models. This scFv could form the basis of future tumour-specific biopharmaceuticals.
Tumour-associated splice variants of fibronectin are a major source of tumour-matrix associated t... more Tumour-associated splice variants of fibronectin are a major source of tumour-matrix associated targets and are proving very successful in the development of clinical agents to treat cancer. One of the first monoclonal antibodies to be produced to this target, murine BC-1, recognises a cryptic epitope in domain 7 of the B-form splice variant (EDB-FN). Antibody fragments based on this immunoglobulin (IgG) were unstable, but BC-1 humanisation provided an opportunity to produce a more stable single-chain Fv (scFv). The variable domains of the humanized BC-1 IgG were sub-cloned and constructed into a scFv (HuBC-1 scFv) which was successfully expressed in Escherichia coli. The scFv retained its conformationally- sensitive epitope recognition and demonstrated a good affinity to the target of around 50 nM as measured by ELISA, Surface Plasmon Resonance and Flow Cytometry. Furthermore, the scFv was thermostable and stable in serum allowing substantial localisation to human tumours grown in mouse xenograft models. This scFv could form the basis of future tumour-specific biopharmaceuticals.
Uploads
Papers by Nor Johdi
and are proving very successful in the development of clinical agents to treat cancer. One of the first
monoclonal antibodies to be produced to this target, murine BC-1, recognises a cryptic epitope in domain
7 of the B-form splice variant (EDB-FN). Antibody fragments based on this immunoglobulin (IgG) were
unstable, but BC-1 humanisation provided an opportunity to produce a more stable single-chain Fv
(scFv). The variable domains of the humanized BC-1 IgG were sub-cloned and constructed into a scFv
(HuBC-1 scFv) which was successfully expressed in Escherichia coli. The scFv retained its conformationally-
sensitive epitope recognition and demonstrated a good affinity to the target of around 50 nM as measured
by ELISA, Surface Plasmon Resonance and Flow Cytometry. Furthermore, the scFv was thermostable
and stable in serum allowing substantial localisation to human tumours grown in mouse xenograft models.
This scFv could form the basis of future tumour-specific biopharmaceuticals.
and are proving very successful in the development of clinical agents to treat cancer. One of the first
monoclonal antibodies to be produced to this target, murine BC-1, recognises a cryptic epitope in domain
7 of the B-form splice variant (EDB-FN). Antibody fragments based on this immunoglobulin (IgG) were
unstable, but BC-1 humanisation provided an opportunity to produce a more stable single-chain Fv
(scFv). The variable domains of the humanized BC-1 IgG were sub-cloned and constructed into a scFv
(HuBC-1 scFv) which was successfully expressed in Escherichia coli. The scFv retained its conformationally-
sensitive epitope recognition and demonstrated a good affinity to the target of around 50 nM as measured
by ELISA, Surface Plasmon Resonance and Flow Cytometry. Furthermore, the scFv was thermostable
and stable in serum allowing substantial localisation to human tumours grown in mouse xenograft models.
This scFv could form the basis of future tumour-specific biopharmaceuticals.